Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3653339 | 0.88 | CHRNA3 (0.42) | MAPTDHFRAGXTF10CAMK2D | |
| SCHEMBL2597597 | 0.86 | DHFR (0.45) | AKR1C3MAPTDHFRCNR2AGXT | |
| SCHEMBL3656991 | 0.84 | ADRA2C (0.47) | MAPTAGXT | |
| SCHEMBL3650599 | 0.81 | F10 (0.44) | AKR1C3MAPTDHFRCNR2AGXT | |
| SCHEMBL3652838 | 0.79 | ALDH1A1 (0.58) | LMNA | |
| SCHEMBL21345910 | 0.76 | MAPK1 (0.50) | AKR1C3MAPTAGXTF10KMO | |
| SCHEMBL16621272 | 0.76 | ALDH1A1 (0.56) | MAPTDHFRAGXTF10KMO | |
| SCHEMBL8064837 | 0.75 | MET (0.51) | KMT2A | |
| SCHEMBL29552004 | 0.75 | AKR1C3 (0.70) | AKR1C3MAPTCNR2LMNAMEN1 | |
| SCHEMBL3651256 | 0.75 | MET (0.51) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571872-B1 | COMPOUNDS | TREHERNE JOHNATHAN MARK (GB) | 2014-12-31 | — | — | EP | disclosed |
| EP-2571872-B1 | COMPOUNDS | TREHERNE JOHNATHAN MARK (GB) | 2014-12-31 | — | — | EP | disclosed |
| EP-2571872-A1 | COMPOUNDS | BTG International Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011144578-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011144578-A1 | COMPOUNDS | SENEXIS LIMITED (GB) | 2011-11-24 | — | — | WO | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| EP-2205317-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | Senexis Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
| WO-2009044160-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | SENEXIS LIMITED (GB) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298325-A1 | PYRIDINE DERIVATIVES FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | HCRTR1, HCRTR2, RTN3 | AKR1C3 423/4885MAPT 312/4885DHFR 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.